Home
Home

Idera Pharmaceuticals

Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis

Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis
Yahoo

2012 Preview: Cancer Immunotherapy Catalysts

2012 Preview: Cancer Immunotherapy Catalysts
Seeking Alpha

Idera Pharmaceuticals Completes $9.5 Million Financing

Idera Pharmaceuticals Completes $9.5 Million Financing
Yahoo/BusinessWire

Idera Pharmaceuticals says partner Merck KGaA will discontinue study of cancer drug

Idera Pharmaceuticals says partner Merck KGaA will discontinue study of cancer drug
Yahoo/AP

Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 in Treatment-Naïve HCV Patients

Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 in Treatment-Naïve HCV Patients
Yahoo/BusinessWire

Idera Pharmaceuticals Presents Data from a Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients at EASL 2011

Idera Pharmaceuticals Presents Data from a Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients at EASL 2011
Yahoo/BusinessWire

News

Idera Pharmaceuticals Presents Phase 1 Data on IMO-2125 Demonstrating Induction of Broad Antiviral Immune Response in Null-Responder HCV Patients
Yahoo/BusinessWire

News

15 Biotech Stocks With the Lowest Put/Call Ratios
Seeking Alpha
»

News

Novartis terminates pact with Idera
Marketwatch
»